Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.

J Antimicrob Chemother 2014 Nov 19;69(11):3142-7. Epub 2014 Jun 19.

Istituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy.

Objectives: To investigate the incidence, treatment and outcome of breakthrough invasive fungal infections (IFIs) in adult acute myeloid leukaemia (AML) patients after posaconazole prophylaxis.

Methods: From January 2010 to April 2012, all consecutive patients with newly diagnosed AML were prospectively registered at 33 participating Italian centres. All cases of IFIs occurring within 30 days after the end of the first induction chemotherapy were recorded. The strategy of antifungal treatment (empirical, pre-emptive or targeted) and the drugs used were analysed. ClinicalTrials.gov code: NCT01315925.

Results: In total, 1192 patients with newly diagnosed AML were enrolled in the study, of whom 510 received posaconazole prophylaxis and were included in the present analysis. Of these patients, 140 (27%) needed systemic antifungal treatment. Among the 127 evaluable cases, an empirical approach was utilized in 102 patients (80%), a pre-emptive approach in 19 patients (15%) and targeted therapy in 6 patients (5%). Only five patients died of IFIs (three in the empirical group and two in the targeted group; 4%). A critical review of IFI diagnoses at 30 days demonstrated that among the patients treated empirically, ∼30% were not affected by IFIs but rather only by fever of unidentified origin. A comparison between the empirical and the pre-emptive groups showed no significant differences regarding the attributable and overall mortalities.

Conclusions: This study confirms that posaconazole prophylaxis reduces the incidence of breakthrough IFIs and does not modify the efficacy of subsequent systemic antifungal treatment, regardless of the approach (empirical or pre-emptive) or the antifungal drug used.

Download full-text PDF

Source
http://jac.oxfordjournals.org/content/early/2014/06/18/jac.d
Web Search
http://www.jac.oxfordjournals.org/cgi/doi/10.1093/jac/dku227
Publisher Site
http://dx.doi.org/10.1093/jac/dku227DOI Listing
November 2014
83 Reads

Publication Analysis

Top Keywords

antifungal treatment
16
empirical pre-emptive
12
posaconazole prophylaxis
12
systemic antifungal
12
patients
9
newly diagnosed
8
diagnosed aml
8
patients newly
8
ifis
5
empirical
5
treatment
5
nct01315925results total
4
total 1192
4
prophylaxis included
4
included analysis
4
fever unidentified
4
∼30% ifis
4
empirically ∼30%
4
1192 patients
4
code nct01315925results
4

Similar Publications